Phamacokinetics and Safety Profiles of DA-5210 10/500mg in Healthy Subjects at Fed State

Dong-A ST

Status and phase: Completed; Phase 1

Conditions: Healthy

Treatments: Drug: DA-5210 10/500mg; Drug: DA-5210-R 10/500mg

Study type: Interventional

Funder types: Industry

Identifiers

NCT05098275

BIBE2021-52

Details and patient eligibility

About

Phamacokinetics and safety profiles of DA-5210 10/500mg in Healthy subjects at Fed State

Enrollment: 38 patients

Sex: All

Ages: 19+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Healthy Volunteers
• BMI between 18 and 30 kg/m2
• Body weight : Male≥50kg, Female≥45kg

Exclusion criteria

• Allergy or Drug hypersensitivity
• Clinically significant Medical History

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: None (Open label)

---

38 participants in 2 patient groups

Sequence A

Experimental group

Treatment:

Drug: DA-5210-R 10/500mg

Drug: DA-5210 10/500mg

Sequence B

Experimental group

Treatment:

Drug: DA-5210-R 10/500mg

Drug: DA-5210 10/500mg